Swiss National Bank lessened its stake in shares of Humana Inc (NYSE:HUM) by 3.3% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 529,826 shares of the insurance provider’s stock after selling 18,200 shares during the period. Swiss National Bank’s holdings in Humana were worth $140,563,000 as of its most recent filing with the SEC.
A number of other large investors also recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Humana by 1.6% during the first quarter. BlackRock Inc. now owns 12,190,049 shares of the insurance provider’s stock valued at $3,242,553,000 after purchasing an additional 186,997 shares during the period. Janus Henderson Group PLC lifted its position in shares of Humana by 3.5% in the first quarter. Janus Henderson Group PLC now owns 3,596,204 shares of the insurance provider’s stock valued at $956,594,000 after acquiring an additional 120,905 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Humana by 8.3% in the fourth quarter. Geode Capital Management LLC now owns 1,773,576 shares of the insurance provider’s stock valued at $507,198,000 after acquiring an additional 135,776 shares in the last quarter. Northern Trust Corp lifted its position in shares of Humana by 0.5% in the first quarter. Northern Trust Corp now owns 1,743,519 shares of the insurance provider’s stock valued at $463,775,000 after acquiring an additional 8,221 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of Humana by 5.3% in the first quarter. Wells Fargo & Company MN now owns 1,343,162 shares of the insurance provider’s stock valued at $357,281,000 after acquiring an additional 67,761 shares in the last quarter. 91.33% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE:HUM traded up $5.94 during mid-day trading on Friday, reaching $297.00. The stock had a trading volume of 605,000 shares, compared to its average volume of 1,156,213. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37. The company has a market cap of $40.03 billion, a P/E ratio of 20.41, a price-to-earnings-growth ratio of 1.28 and a beta of 0.85. Humana Inc has a 1 year low of $225.65 and a 1 year high of $355.88. The business’s 50 day moving average price is $281.97 and its 200 day moving average price is $271.56.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 EPS for the quarter, topping analysts’ consensus estimates of $5.24 by $0.81. The company had revenue of $16.25 billion for the quarter, compared to the consensus estimate of $15.88 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. The firm’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same period in the previous year, the business earned $3.96 earnings per share. Analysts predict that Humana Inc will post 17.63 earnings per share for the current fiscal year.
HUM has been the topic of several research analyst reports. Morgan Stanley lowered their price objective on Humana from $331.00 to $315.00 and set an “overweight” rating on the stock in a research report on Friday, July 12th. Cantor Fitzgerald upgraded Humana from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $300.00 to $345.00 in a research report on Monday, August 12th. SunTrust Banks boosted their price objective on Humana to $340.00 and gave the company a “hold” rating in a research report on Thursday, August 1st. Oppenheimer lowered their price objective on Humana from $373.00 to $350.00 and set an “outperform” rating on the stock in a research report on Thursday, May 2nd. Finally, Credit Suisse Group lowered their price objective on Humana from $352.00 to $315.00 and set an “outperform” rating on the stock in a research report on Thursday, May 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. Humana currently has an average rating of “Buy” and an average target price of $342.26.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Article: Inverted Yield Curve
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.